Table 2.
Clinical variables associated with clinical progression-free survival (n = 75).
| Clinical Characteristics | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
| cPFS | ||||||
| Age > 65 | 0.99 | 0.62–1.60 | 0.984 | - | - | - |
| Male | 0.81 | 0.51–1.30 | 0.393 | - | - | - |
| ECOG ≥ 1 | 1.28 | 0.76–2.18 | 0.355 | - | - | - |
| BMI ≥ 25 | 0.64 | 0.39–1.05 | 0.079 | - | - | - |
| Time from initial dx to stage IV <2 years | 1.82 | 1.14–3.05 | 0.016 | 2.45 | 1.44–4.18 | 0.001 |
| >1 prior systemic therapy | 0.76 | 0.38–1.19 | 0.327 | - | - | - |
| Prior immunotherapy | 1.15 | 0.72–1.86 | 0.557 | - | - | - |
| Prior chemotherapy | 0.78 | 0.37–1.41 | 0.450 | - | - | - |
| ICI regimen: PD1 + CTLA4 vs. PD1 | 1.09 | 0.64–1.87 | 0.745 | - | - | - |
| Lung metastases | 1.16 | 0.71–1.92 | 0.539 | - | - | - |
| Bone metastases | 2.13 | 1.03–4.42 | 0.042 | 1.91 | 0.91–4.00 | 0.086 |
| Largest metastasis diameter ≥6 cm | 1.48 | 0.92–2.40 | 0.105 | - | - | - |
| LDH ≥ 1.5 × ULN | 2.34 | 1.43–3.85 | 0.001 | 2.26 | 1.36–3.77 | 0.002 |
| NLR ≥ 4 | 1.69 | 1.05–2.74 | 0.032 | 2.14 | 1.25–3.65 | 0.005 |